ENYO Pharma announces the successful completion of phase Ib with its FXR agonist EYP001 and the start of phase II studies in two indications, NASH and HBV
Lyon, November 06, 2018 – ENYO Pharma, a clinical stage biotech company developing innovative drug candidates, today announced completion of its phase Ib clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of its FXR agonist compound EYP001 in patients with chronic hepatitis B virus infection (CHBV). The company highlights that EYP001 was well-tolerated by patients and induced a prolonged FXR target engagement after QD dosing over 4 weeks. ENYO Pharma will now initiate two Phase II clinical trials of EYP001 in NASH and CHBV.
Poster presentation with Novadiscovery at the ICSB 2018
ENYO Pharma is pleased to collaborate with Novadiscovery which is presenting at the ISCB today a poster titled “A logical modelling approach to prepare and accelerate the design of ODE models: Application to bile acid metabolism”. The model of bile acids metabolism was developed in the context of a project for ENYO Pharma, where the aim was to model chronic hepatitis B virus and non-alcoholic steatohepatitis (NASH).
Europe Ambition Day 2018
ENYO Pharma was present at the Europe Ambition Day in Lyon on October, 23rd 2018. This event, organized by the Auvergnes-Rhone-Alpes Entreprises, was opened to companies, academics and research centers in the region who wish to increase their chances of receiving funding from the European Commission. During the day, ENYO Pharma had the pleasure to participate to a panel discussion to share its success story and experience regarding the access to European fundings.
The Liver Meeting 2018
San Francisco, USA
9 – 13 November, 2018
AASLD will see you in San Francisco, where more than 9,500 hepatologists and hepatology health professionals from across the nation and around the world will gather at The Liver Meeting® to exchange the latest liver diseases research, discuss treatment outcomes, and interact with colleagues at the annual must-attend even in the science and practice of hepatology.
https://www.aasld.org/events-professional-development/liver-meeting
Participation in the TechShare kick off meeting organized by Euronext
The ENYO team was present at the TechShare kick off meeting on Friday, September 21th, 2018. TechShare is a unique pan-European programme organized by Euronext to boost the funding of innovative companies by financial markets. On this occasion, Euronext has welcomed the 135 non listed most promising European start-ups in order to develop the minimum skills to be listed on stock market. This programme, organized for the 4th consecutive year, has allowed ENYO Pharma to understand the benefits and disadvantages to choose this type of financing to support the company’s growth.
Latest Press Release 